Should I buy or sell BioAtla stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks .

What is BioAtla's stock price target for 2024?

3 analysts have issued twelve-month price targets for BioAtla's stock. Their BCAB share price targets range from $7.00 to $14.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 370.1% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts .

How have BCAB shares performed in 2024?

BioAtla's stock was trading at $2.46 at the beginning of the year. Since then, BCAB stock has decreased by 4.9% and is now trading at $2.34. View the best growth stocks for 2024 here .

Are investors shorting BioAtla?

BioAtla saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,590,000 shares, an increase of 9.0% from the March 15th total of 5,130,000 shares. Based on an average daily volume of 511,500 shares, the short-interest ratio is currently 10.9 days. View BioAtla's Short Interest .

When is BioAtla's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BCAB earnings forecast .

How were BioAtla's earnings last quarter?

BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.12.

What ETF holds BioAtla's stock?

Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.

When did BioAtla IPO?

BioAtla (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.

How do I buy shares of BioAtla?

Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCAB

BioAtla (BCAB) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BCAB Stock Alerts

$2.14

-0.29 (-11.93%)

(As of 03:15 PM ET)

Compare

Today's Range: $2.14
▼
$2.51
50-Day Range: $2.26
▼
$3.92
52-Week Range: $1.24
▼
$4.07

Volume: 626,937 shs
Average Volume: 502,276 shs
Market Capitalization: $102.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get BioAtla alerts:

BioAtla MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 370.1% Upside
$11.00 Price Target
Short Interest: Bearish
11.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.93) to ($1.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

703rd out of 918 stocks

Biological Products, Except Diagnostic Industry

118th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
BioAtla has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioAtla has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.62% of the outstanding shares of BioAtla have been sold short.
Short Interest Ratio / Days to Cover
BioAtla has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in BioAtla has recently increased by 8.97%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioAtla does not currently pay a dividend.
Dividend Growth
BioAtla does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCAB.

3.6

News and Social Media Coverage

News Sentiment
BioAtla has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.
Search Interest
8 people have searched for BCAB on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
MarketBeat Follows
12 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioAtla insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.38% of the stock of BioAtla is held by insiders.
Percentage Held by Institutions
77.23% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioAtla are expected to grow in the coming year, from ($1.93) to ($1.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioAtla is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioAtla is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioAtla has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About BioAtla Stock (NASDAQ:BCAB)

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

BCAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCAB Stock News Headlines

April 17, 2024 | americanbankingnews.com

BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 9.0% in March

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for BioAtla on Strong Clinical Pipeline and Financial Stability

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 5, 2024 | seekingalpha.com

GRIN, WOOF and MRNS are among after hour movers

March 27, 2024 | markets.businessinsider.com

Optimistic Outlook for BioAtla’s Pipeline Progression and Potential Partnerships

March 27, 2024 | finance.yahoo.com

BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript

March 26, 2024 | benzinga.com

BioAtla: Q4 Earnings Insights

March 26, 2024 | finance.yahoo.com

BioAtla Inc (BCAB) Posts Q4 and Full Year 2023 Financial Results

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | globenewswire.com

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

March 25, 2024 | benzinga.com

Preview: BioAtla's Earnings

March 19, 2024 | globenewswire.com

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

March 7, 2024 | globenewswire.com

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 6, 2024 | edition.cnn.com

BioAtla, Inc.

January 24, 2024 | markets.businessinsider.com

Strong Buy for BioAtla: Promising ADC Developments and Strategic Oncology Pipeline

January 10, 2024 | markets.businessinsider.com

Buy Rating for BioAtla Amid Robust Pipeline and Encouraging Clinical Trials

January 1, 2024 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on BioAtla (BCAB)

December 23, 2023 | finance.yahoo.com

Co-Founder of BioAtla Jay Short Buys 2.3% More Shares

December 21, 2023 | msn.com

BioAtla CEO purchases 50K common shares

December 20, 2023 | finance.yahoo.com

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023 | markets.businessinsider.com

Strong Buy Rating for BioAtla Reflects Potential of BA3071 and Promising Clinical Results

December 15, 2023 | finance.yahoo.com

After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gain

December 14, 2023 | markets.businessinsider.com

Buy Rating Affirmed for BioAtla Amid Promising BA3071 Clinical Data and Favorable Safety Profile

December 13, 2023 | finance.yahoo.com

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

December 12, 2023 | morningstar.com

BioAtla Inc Ordinary Shares

December 6, 2023 | finance.yahoo.com

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

December 5, 2023 | markets.businessinsider.com

Strong Buy Rating for BioAtla Amid BA3011’s Promising Efficacy and Strategic FDA Engagement

See More Headlines

Receive BCAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BCAB
CUSIP: N/A
CIK: 1826892
Web: www.bioatla.com
Phone: 858-558-0708
Fax: N/A
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $14.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +414.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -110.65%
Return on Assets: -75.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.11
Quick Ratio: 4.11

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 411.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.47 per share
Price / Book: 1.46

Miscellaneous

Outstanding Shares: 48,100,000
Free Float: 44,066,000
Market Cap: $102.93 million
Optionable: Optionable
Beta: 1.08

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Jay M. Short Ph.D. (Age 66)
Co-Founder, CEO & Chairman
Comp: $1.06M
Mr. Richard A. Waldron (Age 70)
Senior VP & CFO
Comp: $617.62k
Dr. Eric L. Sievers M.D. (Age 60)
Chief Medical Officer
Comp: $608.18k
Mr. Christian J. Vasquez (Age 48)
Senior VP of Finance, Corporate Controller & Secretary
Comp: $408.75k
Lisa M. Pelton
Accounting Manager
Ms. Susie Melody
Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D.
Senior Vice President of Research & Development
Dr. Gerhard Frey Ph.D.
Senior Vice President of Technology Development
Ms. Monica Sullivan
Senior Vice President of Intellectual Property & Contracts
Ms. Sheri Lydick
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCAB Stock Analysis - Frequently Asked Questions

Should I buy or sell BioAtla stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCAB shares.
View BCAB analyst ratings or view top-rated stocks.
What is BioAtla's stock price target for 2024?: 3 analysts have issued twelve-month price targets for BioAtla's stock. Their BCAB share price targets range from $7.00 to $14.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 370.1% from the stock's current price.
View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts.
How have BCAB shares performed in 2024?: BioAtla's stock was trading at $2.46 at the beginning of the year. Since then, BCAB stock has decreased by 4.9% and is now trading at $2.34.
View the best growth stocks for 2024 here.
Are investors shorting BioAtla?: BioAtla saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,590,000 shares, an increase of 9.0% from the March 15th total of 5,130,000 shares. Based on an average daily volume of 511,500 shares, the short-interest ratio is currently 10.9 days.
View BioAtla's Short Interest.
When is BioAtla's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BCAB earnings forecast.

How were BioAtla's earnings last quarter?: BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.12.
What ETF holds BioAtla's stock?: Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio.
When did BioAtla IPO?: BioAtla (BCAB) raised $150 million in an IPO on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG served as the underwriters for the IPO.
How do I buy shares of BioAtla?: Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCAB) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial